Lisaftoclax
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 464 patients (estimated)
- Sponsors
- Ascentage Pharma Group Inc.
- Tags
- BCL-2 Inhibitor, Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 4 days ago
- SparkCures ID
- 2010
- NCT Identifier
- NCT06641414
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.